Trial Profile
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Status:
Discontinued
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 09 Sep 2020
Price :
$35
*
At a glance
- Drugs Brincidofovir (Primary)
- Indications Adenovirus infections
- Focus Expanded access; Therapeutic Use
- Sponsors Chimerix
- 09 May 2019 Status changed from recruiting to discontinued, according to a Chimerix media release.
- 07 Nov 2015 New trial record